COVID-19 Updates

Visit UC San Diego's Coronavirus portal for the latest information for the campus community.

Cancer Control Program

Areas of Interest: 

  • Hepatocellular carcinoma
  • Non-alcoholic Fatty Liver Disease
  • Alcohol-associated Liver Disease
  • Non-invasive biomarkers
  • Genetics
  • Epidemiology
  • Clinical trial design
  • Integrated OMICS
Active or most recent cancer-related grant (s):
  • U01DK130190 “San Diego Cirrhosis Clinical Research Network”
  • U01DK061734 “Clinical Research on Nonalcoholic Fatty Liver Disease”
  • U01AA029019 “Novel IL-23 inhibitor for the treatment of alcohol-associated liver disease”
  • R01DK124318 “Non-invasive screening of diabetics for advanced fibrosis due to NAFLD”
  • P01HL147835 “Role of liver fat and fibrosis in human CVD risk phenotypes.” R01DK121378 “Ancillary Studies of NAFLD and NASH in HIV infected Adults”
  • P30DK120515 “San Diego Digestive Disease Research Center Human Translational Core”
Most important recent cancer-related publications:
  • Huang DQ, Singal AG, Kono Y, Tan DJH, El-Serag HB, Loomba R.Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metab. 2022
  • Tan DJH, Ng CH, Lin SY, Pan XH, Tay P, Lim WH, Teng M, Syn N, Lim G, Yong JN, Quek J, Xiao J, Dan YY, Siddiqui MS, Sanyal AJ, Muthiah MD, Loomba R, Huang DQ. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. Lancet Oncol. 2022
  • Strnad P, Mandorfer M, Choudhury G, Griffiths W, Trautwein C, Loomba R, Schluep T, Chang T, Yi M, Given BD, Hamilton JC, San Martin J, Teckman JH. Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency. N Engl J Med. 2022

Resources: